1Meta-Analysis2024
Lütkemeyer C, Pasqualotto E, Ferreira ROM, Chavez MP, Petris I, Dos Santos HV · Arch Endocrinol Metab (2024)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
51 peer-reviewed studies
What the evidence says
Orforglipron doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2023–2026 with a typical study size of 559 participants.
Based on 51 studies · 11 meta-analyses · 18 RCTs · 2,067 total participants
Confidence
High confidenceBy outcome
51 studies in the last 5 years · Latest meta-analysis: 2026
Lütkemeyer C, Pasqualotto E, Ferreira ROM, Chavez MP, Petris I, Dos Santos HV · Arch Endocrinol Metab (2024)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Karakasis P, Patoulias D, Pamporis K, Stachteas P, Bougioukas KI, Klisic A · Metabolism (2023)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Hageen AW, Gadelmawla AF, Saleh AO, Mohamed MR, Abdallfatah A, Elsekhary A · Endocrinol Diabetes Metab (2026)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Nong K, Jeppesen BT, Shi Q, Agoritsas T, Guyatt GH, White H · BMJ (2025)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Hammad N, Ramadan AM, Nazmy A, Elazab A, Abdelaziz A · Diabetes Technol Ther (2026)
No plain-language summary recorded for this citation — open the paper to read its abstract.
In plain English: At week 40, the estimated mean change from baseline in the glycated hemoglobin level was -1.24 percentage points with the 3-mg dose, -1.47 with the 12-mg dose, -1.48 with the 36-mg dose, and -0.41 with placebo.
Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, Cox D, Wu WS, Liu R, Li J, Fernández Landó L, Denning M, Ludwig L, Chen Y; ACHIEVE-1 Trial Investigators. · N Engl J Med (2025)
Hegaz MG, Aboud MYA, Kamel AII, Naveed MA, Elsayed OG, Sorathia AZ · BMC Endocr Disord (2026)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Li H, Yu G, Huang Q, Yang B, Nie J, Liu Y · Biomed Pharmacother (2024)
No plain-language summary recorded for this citation — open the paper to read its abstract.
In plain English: Orforglipron significantly improved glycemic and lipid parameters in patients with obesity, demonstrating dose-dependent efficacy with maximal benefits at higher doses.
Pandey RK, Jan M, Mohammad A, Jawaid KA, Naveed M, Abid MA, Amir AB, Ahmed S, Safiullah M, Bhatti MI, Iftikhar S, Saddique MN, Alfalh W, Omar RMB, Abu Dawood H. · Endocrinology, diabetes & metabolism (2025)
In plain English: Change from baseline in mean HbA1c was -1.23%, -1.50%, and -1.56% with orforglipron 3 mg, 12 mg, and 36 mg, respectively, versus -0.81% with dapagliflozin 10 mg.
Welch M, Forst T, Jia W, Del Pino PO, Denning M, Wu WS, Li J, Liu R, Eifu M, Chen Y; ACHIEVE-2 Trial Investigators. · Lancet (2026)
Takrori E, Peshin S, Singal S · Medicina (Kaunas) (2025)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Alsaqaaby MS, Cooney S, le Roux CW, Pournaras DJ · Lancet Diabetes Endocrinol (2024)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Luna Ceron E, Reddy SD, Kattamuri L, Muvva DM, Chozet L, Bright T · J Brown Hosp Med (2025)
No plain-language summary recorded for this citation — open the paper to read its abstract.
In plain English: Reported as primary pooled effects, orforglipron improves HbA1c, weight, BMI, SBP, and fasting plasma glucose, with a class-consistent increase in heart rate and no excess in hypoglycaemia or serious adverse events versus placebo.
Jamal A, Khan S, Qadri M, Shah A, Iftikhar H, Fatima E, Ahmad M, Sikandar M, Jawed I, Muneeb M, Mohmand MS, Bacha Z, Khan BW, Jamal T, Khalid AA, Khan MI, Zulkaif M. · Acta diabetologica (2026)
In plain English: At week 40, the mean changes from baseline in HbA1c were -1.58%, -1.88%, and -1.82% with orforglipron 3 mg, 12 mg, and 36 mg once daily, respectively, vs -0.79% with placebo.
Giorgino F, D'Souza S, Ludwig L, Kiyosue A, Ibriga H, Rha H, Denning M, Wu WS, Fernández Landó L, Tobian J. · JAMA (2026)
Frias JP, Hsia S, Eyde S, Liu R, Ma X, Konig M · Lancet (2023)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K · N Engl J Med (2025)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Horn DB, Ryan DH, Kis SG, Alves B, Mu Y, Kim SG · Lancet (2026)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R · N Engl J Med (2023)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Pratt E, Ma X, Liu R, Robins D, Coskun T, Sloop KW · Diabetes Obes Metab (2023)
No plain-language summary recorded for this citation — open the paper to read its abstract.